Equities analysts forecast that Kura Oncology, Inc. (NASDAQ:KURA) will post earnings of ($0.54) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Kura Oncology’s earnings, with the highest EPS estimate coming in at ($0.51) and the lowest estimate coming in at ($0.62). Kura Oncology posted earnings per share of ($0.45) during the same quarter last year, which indicates a negative year over year growth rate of 20%. The firm is expected to announce its next earnings results on Wednesday, February 23rd.
On average, analysts expect that Kura Oncology will report full-year earnings of ($2.01) per share for the current year, with EPS estimates ranging from ($2.10) to ($1.98). For the next financial year, analysts anticipate that the firm will post earnings of ($2.27) per share, with EPS estimates ranging from ($2.85) to ($1.99). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Kura Oncology.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, November 4th. The company reported ($0.50) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.04. During the same period in the prior year, the business earned ($0.42) earnings per share.
A number of hedge funds have recently modified their holdings of the business. Marshall Wace LLP purchased a new stake in shares of Kura Oncology in the first quarter worth approximately $372,000. Dimensional Fund Advisors LP raised its holdings in shares of Kura Oncology by 26.3% in the first quarter. Dimensional Fund Advisors LP now owns 819,092 shares of the company’s stock worth $23,104,000 after buying an additional 170,582 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Kura Oncology by 33.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,746 shares of the company’s stock worth $897,000 after buying an additional 7,924 shares during the period. Royal Bank of Canada raised its holdings in shares of Kura Oncology by 1,349.6% in the first quarter. Royal Bank of Canada now owns 9,843 shares of the company’s stock worth $278,000 after buying an additional 9,164 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its holdings in shares of Kura Oncology by 318.5% in the first quarter. Schonfeld Strategic Advisors LLC now owns 84,702 shares of the company’s stock worth $2,395,000 after buying an additional 64,464 shares during the period.
Shares of NASDAQ KURA traded down $2.58 during mid-day trading on Thursday, hitting $14.02. 6,681,951 shares of the stock traded hands, compared to its average volume of 677,911. Kura Oncology has a 52 week low of $12.32 and a 52 week high of $43.00. The company has a market cap of $933.12 million, a price-to-earnings ratio of -7.30 and a beta of 1.58. The stock has a fifty day moving average price of $18.24 and a 200-day moving average price of $19.58.
About Kura Oncology
Kura Oncology, Inc operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias.
Featured Story: Asset Allocation and Your Retirement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.